Literature DB >> 23313857

A comparison of etanercept vs. infliximab for the treatment of post-arrest myocardial dysfunction in a swine model of ventricular fibrillation.

Scott T Youngquist1, James T Niemann, Atman P Shah, Joseph L Thomas, John P Rosborough.   

Abstract

AIMS: To compare the effects of two TNF-α antagonists, etanercept and infliximab, on post-cardiac arrest hemodynamics and global left ventricular function (LV) in a swine model following ventricular fibrillation (VF).
METHODS: Domestic swine (n=30) were placed under general anesthesia and instrumented before VF was induced electrically. After 7 min of VF, standard ACLS resuscitation was performed. Animals achieving return of spontaneous circulation (ROSC) were randomized to immediately receive infliximab (5 mg/kg, n=10) or etanercept (0.3 mg/kg [4 mg/m(2)], n=10) or vehicle (250 mL normal saline [NS], n=10) and LV function and hemodynamics were monitored for 3 h.
RESULTS: Following ROSC, mean arterial pressure (MAP), stroke work (SW), and LV dP/dt fell from pre-arrest values in all groups. However, at the 30 min nadir, infliximab-treated animals had higher MAP than either the NS group (difference 14.4 mm Hg, 95% confidence interval [CI] 4.2-24.7) or the etanercept group (19.2 mm Hg, 95% CI 9.0-29.5), higher SW than the NS group (10.3 gm-m, 95% CI 5.1-15.5) or the etanercept group (8.9 gm-m, 95% CI 4.0-14.4) and greater LV dP/dt than the NS group (282.9 mm Hg/s, 95% CI 169.6-386.1 higher with infliximab) or the etanercep group (228.9 mm Hg/s, 95% CI 115.6-342.2 higher with infliximab).
CONCLUSIONS: Only infliximab demonstrated a beneficial effect on post cardiac arrest hemodynamics and LV function in this swine model. Etanercept was no better in this regard than saline.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23313857      PMCID: PMC3679243          DOI: 10.1016/j.resuscitation.2012.12.028

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  28 in total

1.  First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults.

Authors:  Vinay M Nadkarni; Gregory Luke Larkin; Mary Ann Peberdy; Scott M Carey; William Kaye; Mary E Mancini; Graham Nichol; Tanya Lane-Truitt; Jerry Potts; Joseph P Ornato; Robert A Berg
Journal:  JAMA       Date:  2006-01-04       Impact factor: 56.272

2.  Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction.

Authors:  Andreas Skyschally; Petra Gres; Simone Hoffmann; Michael Haude; Raimund Erbel; Rainer Schulz; Gerd Heusch
Journal:  Circ Res       Date:  2006-12-14       Impact factor: 17.367

3.  Immediate coronary angiography in survivors of out-of-hospital cardiac arrest.

Authors:  C M Spaulding; L M Joly; A Rosenberg; M Monchi; S N Weber; J F Dhainaut; P Carli
Journal:  N Engl J Med       Date:  1997-06-05       Impact factor: 91.245

4.  Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness.

Authors:  T Gulick; M K Chung; S J Pieper; L G Lange; G F Schreiner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

Authors:  A Deswal; B Bozkurt; Y Seta; S Parilti-Eiswirth; F A Hayes; C Blosch; D L Mann
Journal:  Circulation       Date:  1999-06-29       Impact factor: 29.690

6.  In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure.

Authors:  Gordon W Moe; Jose Marin-Garcia; Andrea Konig; Michael Goldenthal; Xiangru Lu; Qingping Feng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-06-17       Impact factor: 4.733

7.  Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

Authors:  Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

8.  Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.

Authors:  Eugene S Chung; Milton Packer; Kim Hung Lo; Adedigbo A Fasanmade; James T Willerson
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

9.  Is all ventricular fibrillation the same? A comparison of ischemically induced with electrically induced ventricular fibrillation in a porcine cardiac arrest and resuscitation model.

Authors:  James T Niemann; John P Rosborough; Scott Youngquist; Jay Thomas; Roger J Lewis
Journal:  Crit Care Med       Date:  2007-05       Impact factor: 7.598

10.  Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs.

Authors:  Tadahiko Kohno; Lei-Ting T Tam; Seth R Stevens; James S Louie
Journal:  J Investig Dermatol Symp Proc       Date:  2007-05
View more
  6 in total

1.  Right ventricular dysfunction after resuscitation predicts poor outcomes in cardiac arrest patients independent of left ventricular function.

Authors:  Vimal Ramjee; Anne V Grossestreuer; Yuan Yao; Sarah M Perman; Marion Leary; James N Kirkpatrick; Paul R Forfia; Daniel M Kolansky; Benjamin S Abella; David F Gaieski
Journal:  Resuscitation       Date:  2015-08-28       Impact factor: 5.262

Review 2.  Myocardial Dysfunction and Shock after Cardiac Arrest.

Authors:  Jacob C Jentzer; Meshe D Chonde; Cameron Dezfulian
Journal:  Biomed Res Int       Date:  2015-09-02       Impact factor: 3.411

3.  Neuronal injury and tumor necrosis factor-alpha immunoreactivity in the rat hippocampus in the early period of asphyxia-induced cardiac arrest under normothermia.

Authors:  Hyun-Jin Tae; Il Jun Kang; Tae-Kyeong Lee; Jeong Hwi Cho; Jae-Chul Lee; Myoung Cheol Shin; Yoon Sung Kim; Jun Hwi Cho; Jong-Dai Kim; Ji Hyeon Ahn; Joon Ha Park; In-Shik Kim; Hyang-Ah Lee; Yang Hee Kim; Moo-Ho Won; Young Joo Lee
Journal:  Neural Regen Res       Date:  2017-12       Impact factor: 5.135

4.  Changes in histopathology and tumor necrosis factor-α levels in the hearts of rats following asphyxial cardiac arrest.

Authors:  Jung Hoon Lee; Tae-Kyeong Lee; In Hye Kim; Jae Chul Lee; Moo-Ho Won; Joon Ha Park; Ji Hyeon Ahn; Myoung Chul Shin; Taek Geun Ohk; Joong Bum Moon; Jun Hwi Cho; Chan Woo Park; Hyun-Jin Tae
Journal:  Clin Exp Emerg Med       Date:  2017-09-30

5.  The relationship between low survival and acute increase of tumor necrosis factor α expression in the lung in a rat model of asphyxial cardiac arrest.

Authors:  Yoonsoo Park; Hyun-Jin Tae; Jeong Hwi Cho; In-Shik Kim; Taek Geun Ohk; Chan Woo Park; Joong Bum Moon; Myoung Cheol Shin; Tae-Kyeong Lee; Jae-Chul Lee; Joon Ha Park; Ji Hyeon Ahn; Seok Hoon Kang; Moo-Ho Won; Jun Hwi Cho
Journal:  Anat Cell Biol       Date:  2018-06-27

6.  Gene-selective transcription promotes the inhibition of tissue reparative macrophages by TNF.

Authors:  Stefanie Dichtl; David E Sanin; Carolin K Koss; Sebastian Willenborg; Andreas Petzold; Maria C Tanzer; Andreas Dahl; Agnieszka M Kabat; Laura Lindenthal; Leonie Zeitler; Sabrina Satzinger; Alexander Strasser; Matthias Mann; Axel Roers; Sabine A Eming; Karim C El Kasmi; Edward J Pearce; Peter J Murray
Journal:  Life Sci Alliance       Date:  2022-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.